Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil once-daily dose-ranging study in men with benign prostatic hyperplasia
2006-001958-27Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in benign prostatic hyperplasia (BPH) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in total International Prostate Symptom Score from baseline to Week 12. Started May 2006; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2006-001958-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001958-27.